Zedira offers its expertise in the field of transglutaminase to be an ally in drug development for a limited number of partners.
Until now, preclinical and clinical development targeting transglutaminase suffers from a lack of potent and selective blockers. Zedira has overcome this limitation.

Partnering with Zedira will provide access to our transglutaminase-specific drug development platform, which is composed of 4 modules:

Zedira Service Compound lirary
Medicinal chemists synthesized more than 1,000 small molecules targeting either TG2 or FXIIIa covering a remarkable physicochemical space. We are confident not only having the most potent drug able molecules in hand, some of them oral available, but also having a unique knowledge about candidate drugs tailor-made for distinct indications on the horizon.

 
Zedira Service Screening
96-well screening platform for hit finding, lead optimization and profiling.

Besides the identification of new molecules blocking tissue transglutaminase, the platform allows for profiling selectivity against all human transglutaminase iso-enzymes (FXIII, TG1, TG2, TG3, TG4, TG5, TG6, and TG7). In addition, animal derived transglutaminases are available for pre-evaluation of inhibitory activities in animal models.

 
Zedira Service Cell based assays
Will inhibitors penetrate into cells and will they inhibit the targeted transglutaminase at intracellular conditions?

These questions are addressed by our cell based assays.

 
Zedira Service Crystallization
Co-crystals from highly purified transglutaminase-inhibitor-conjugates are the prerequisite for x-ray diffraction and consecutive structure analysis.
Understanding the interaction of the inhibitors to the targets on a molecular level allows in silico design of improved transglutaminase inhibitors.


Zedira
is a reliable partner complementing the skills of pharmaceutical companies in the transglutaminase sector in order to create extra value and shorten development times.
   

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • MEDICA

    13.11.2017 - 16.11.2017
    Düsseldorf, Germany

  • Gordon Research Conference on: Transglutaminases in Human Disease Processes

    16.06.2018 - 17.06.2018
    Les Diablerets, Switzerland